Skip to content
Companies

Nuclein

Handheld rapid PCR testing for clinics

Raised to date

$28.3M

of $41.1M offered across 3 Form D filings

Still open
$12.8M
Investors
49
Last filed
Aug 14, 2026

About

Nuclein is a molecular diagnostics company that builds handheld, point-of-care PCR testing systems. Its DASH Rapid PCR System is a compact, battery-capable instrument that runs disposable single-use cartridges and returns lab-quality PCR results in about 15 minutes with roughly one minute of hands-on time. The DASH SARS-CoV-2 & Flu A/B Test is FDA-cleared and CLIA-waived, so it can be run in urgent care, pediatric and primary care settings without sending samples to a central lab. Nuclein was founded in 2017 by Alan Blake and Dr. Richard Crockett and is based in Austin, Texas.

Nuclein miniaturizes full sample-to-answer PCR into a hand-held, disposable-cartridge device with room-temperature cartridge storage, giving CLIA-waived clinics lab-grade molecular results in 15 minutes without the cold chain, benchtop analyzer, or send-out lab that conventional PCR requires.

Funding

$25M, first sold Jul 2025$19.1M sold$5.9M still openJul 2025Jan 2026Jul
Now
  • DebtFiled Aug 14, 2026Form D/A
    $9.3M/ $16.1M
  • DebtFiled Jun 22, 2026Form D
    $1.3M/ $11.1M
  • DebtFiled Apr 27, 2026Form D/A
    $19.1M/ $25M

Product

DASH Rapid PCR System

In vitro diagnostic instrument

A compact point-of-care PCR instrument (15"D x 11"H x 4"W) that runs disposable sample-to-answer cartridges and reports multiplex molecular results in about 15 minutes, with Wi-Fi and cloud connectivity for result reporting.

  • Results in approximately 15 minutes with ~1 minute of hands-on time
  • FDA-cleared and CLIA-waived SARS-CoV-2 & Flu A/B test
  • Room-temperature cartridge storage, no cold chain required

Built for

Point-of-care healthcare providers — urgent care clinics, pediatric practices, and primary care offices — that want CLIA-waived molecular testing on site

People on file